Is CYTOKINETICS INC (CYTK) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 17.4% / 30% | 11.9% / 30% | 0.2% / 30% | 55.0% / 5% | ✗ NOT HALAL |
| DJIM | 17.4% / 33% | 11.9% / 33% | 0.2% / 33% | 55.0% / 5% | ✗ NOT HALAL |
| MSCI | 90.2% / 33% | 61.9% / 33% | 1.2% / 33% | 55.0% / 5% | ✗ NOT HALAL |
| S&P | 17.4% / 33% | 11.9% / 33% | 0.2% / 33% | 55.0% / 5% | ✗ NOT HALAL |
| FTSE | 90.2% / 33% | 61.9% / 33% | 1.2% / 50% | 55.0% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -1004.6% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -27.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$510M |
| Free Cash Flow | -$535M |
| Total Debt | $1.3B |
| Current Ratio | 4.5 |
| Total Assets | $1.4B |
Price & Trading
| Last Close | $63.48 |
| 50-Day MA | $63.53 |
| 200-Day MA | $53.99 |
| Avg Volume | 1.9M |
| Beta | 0.5 |
|
52-Week Range
$29.31
| |
About CYTOKINETICS INC (CYTK)
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CYTOKINETICS INC (CYTK) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CYTOKINETICS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CYTOKINETICS INC's debt ratio?
CYTOKINETICS INC's debt ratio is 17.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 90.2%.
What are CYTOKINETICS INC's key financial metrics?
CYTOKINETICS INC has a market capitalization of $7.7B, and revenue of $88M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.